MoonLake Immunotherapeutics Balance Sheet
MLTX / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
MoonLake Immunotherapeutics had $424M in total assets and $304M in shareholders' equity as of FY2025. Total debt was $74M against $335M in cash, resulting in a $260M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $334.5M | $180.4M | $451.2M | $39.5M | $8.0M | $1.3M |
| Current Assets | $421.7M | $474.3M | $514.2M | $76.5M | $9.6M | $1.6M |
| PP&E (Net) | $577.0K | $722.0K | $320.9K | $49.4K | $45.7K | - |
| Total Assets | $424.4M | $477.9M | $526.5M | $76.8M | $9.7M | $116.6M |
| Current Liabilities | $45.5M | $22.5M | $10.0M | $7.7M | $21.1M | $125.2K |
| Total Debt | $74.1M | $0 | - | - | - | - |
| Shareholders' Equity | $304.5M | $446.8M | $513.5M | $68.8M | -$11.6M | -$2.5M |